Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron for Radiation Induced Nausea and Vomiting
NCT02388750Phase 2Completed
- Start
- Apr 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palonosetron in radiation-induced nausea and vomiting (RINV) (2 arms). Primary endpoint: Efficacy for prevention of nausea and vomiting events. Started Apr 2015; status: completed.
02
Drugs
palonosetron
03
Conditions
radiation-induced nausea and vomiting (RINV)
Beyond the preview
Go deeper on NCT02388750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388750.